Results 11 to 20 of about 409,363 (246)
Intralymphatic immunotherapy [PDF]
World Allergy Organization Journal, 2015 Gold Standard allergen-specific immunotherapy is associated with low efficacy because it requires either many subcutaneous injections of allergen or even more numerous sublingual allergen administrations to achieve amelioration of symptoms. Intralymphatic vaccination can maximize immunogenicity and hence efficacy.
Gabriela Senti, Thomas M Kündig
openaire +3 more sources
Modulation of Endosome Function, Vesicle Trafficking and Autophagy by Human Herpesviruses
Cells, 2021 Human herpesviruses are a ubiquitous family of viruses that infect individuals of all ages and are present at a high prevalence worldwide. Herpesviruses are responsible for a broad spectrum of diseases, ranging from skin and mucosal lesions to blindness ...
Eduardo I. Tognarelli +6 more
doaj +1 more source
Nature Communications, 2022 Plasma B cells (PC) are a potential source for protein replacement as they could be engineered to secrete protein other than antibody. Here the authors engineer B cells to express exogenous proteins and demonstrate that these cells can persist long term ...
Rene Yu-Hong Cheng +11 more
doaj +1 more source
The alarmin IL33 orchestrates type 2 immune-mediated control of thymus regeneration
Nature Communications, 2023 As the primary site of T-cell development, the thymus dictates immune competency of the host. The rates of thymus function are not constant, and thymus regeneration is essential to restore new T-cell production following tissue damage from environmental ...
Emilie J. Cosway +7 more
doaj +1 more source
Persistent mutant oncogene specific T cells in two patients benefitting from anti-PD-1
Journal for ImmunoTherapy of Cancer, 2019 Background Several predictive biomarkers are currently approved or are under investigation for the selection of patients for checkpoint blockade. Tumor PD-L1 expression is used for stratification of non-small cell lung (NSCLC) patients, with tumor ...
Kellie N. Smith +40 more
doaj +1 more source
Neurodegenerative Diseases, 2015 In recent years, tau immunotherapy has advanced from proof-of-concept studies [Sigurdsson EM, NIH R01AG020197, 2001; Asuni AA, et al: J Neurosci 2007;27:9115-9129], which have now been confirmed and extended by us and others. Phase I clinical trials on active and passive tau immunizations are being conducted, with several additional passive tau ...
openaire +2 more sources
Intratumoral neoadjuvant immunotherapy based on the BO-112 viral RNA mimetic
OncoImmunology, 2023 BO-112 is a poly I:C-based viral mimetic that exerts anti-tumor efficacy when intratumorally delivered in mouse models. Intratumoral BO-112 synergizes in mice with systemic anti-PD-1 mAbs and this combination has attained efficacy in PD1-refractory ...
Maite Alvarez +16 more
doaj +1 more source
OncoImmunology, 2018 Memory CD8+ T cell responses have the potential to mediate long-lasting protection against cancers. Resident memory CD8+ T (Trm) cells stably reside in non-lymphoid tissues and mediate superior innate and adaptive immunity against pathogens.
Felipe Gálvez-Cancino +13 more
doaj +1 more source
Recent advances in immunotherapies: from infection and autoimmunity, to cancer, and back again
Genome Medicine, 2018 For at least 300 years the immune system has been targeted to improve human health. Decades of work advancing immunotherapies against infection and autoimmunity paved the way for the current explosion in cancer immunotherapies.
Samantha L. Bucktrout +2 more
doaj +1 more source